Lidocaine hydrochloride
Based on 23 publication(s) in Google Scholar
Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor.
For research use only. We do not sell to patients.
- Purity: 99.84%
- CAS No.: 73-78-9
- Formula: C14H23ClN2O
- Molecular Weight:270.80
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) Lidocaine hydrochloride
More- Nat Methods. 2021 Jul;18(7):788-798. [Abstract]
- Nat Commun. 2026 Feb 10;17(1):2559. [Abstract]
- Sci Adv. 2026 Mar 6;12(10):eadw0891. [Abstract]
- Sci Adv. 2025 Dec 5;11(49):eadw7972. [Abstract]
- J Neuroinflammation. 2017 Nov 2;14(1):211. [Abstract]
- Stem Cell Res Ther. 2021 Feb 4;12(1):107. [Abstract]
- Transl Psychiatry. 2025 May 17;15(1):172. [Abstract]
- J Ethnopharmacol. 2025 May 12:347:119803. [Abstract]
- Biomater Adv. 2026 Jan:178:214452. [Abstract]
- Drug Des Devel Ther. 2024 Apr 9:18:1103-1114. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Int Immunopharmacol. 2023 Feb:115:109706. [Abstract]
- Mol Med Rep. 2022 May;25(5):150. [Abstract]
- PLoS Pathog. 2023 Feb 3;19(2):e1011126. [Abstract]
- Phytochemistry. 2026 Aug:248:114929. [Abstract]
- Reprod Toxicol. 2025 May:134:108895. [Abstract]
- Eur Spine J. 2022 Nov;31(11):2960-2971. [Abstract]
- J Phys D Appl Phys. 2019 Aug; 52(46).
- Neurogastroenterol Motil. 2023 Nov;35(11):e14677. [Abstract]
- PLoS One. 2025 Nov 4;20(11):e0335932. [Abstract]
- Dig Dis Sci. 2021 Dec;66(12):4384-4397. [Abstract]
- Eng Proc. 2026 Jan 14;110(1):7.
- University of Glasgow. 2023.
-
RT-PCR
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
Cell Imaging/Staining
All MEK Isoforms
More
Biological Activity
|
MEK |
ERK |
NF-κB |
Lidocaine hydrochloride (Lignocaine hydrochloride) (10 nM; 48 hours) decreases significantly cell proliferation[2].
Lidocaine hydrochloride (1-10 nM; 24-72 hours) inhibits cell viability and achieves the most suppressing effects at the concentration of 10 nM and treatment time 48 hours[2].
Lidocaine hydrochloride (10 nM; 48 hours) increases significantly the apoptotic cell rate[2].
Lidocaine hydrochloride (10 nM; 48 hours) down-regulates Cyclin D1 and up-regulates p21 expression significantly[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:The human gastric cancer cell line MKN45
-
Concentration:10 nM
-
Incubation Time:48 hours
-
Result:Decreased significantly cell proliferation.
-
Cell Line:The human gastric cancer cell line MKN45
-
Concentration:1, 5 and 10 nM
-
Incubation Time:24, 48, 72 hours
-
Result:Inhibited MKN45 cell viability.
-
Cell Line:The human gastric cancer cell line MKN45
-
Concentration:10 nM
-
Incubation Time:48 hours
-
Result:Increased significantly the apoptotic cell rate.
-
Cell Line:The human gastric cancer cell line MKN45
-
Concentration:10 nM
-
Incubation Time:48 hours
-
Result:Down-regulated Cyclin D1 and up-regulated p21 expression significantly.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 73-78-9
-
Appearance Solid
-
Molecular Weight 270.80
-
Formula C14H23ClN2O
-
Color White to off-white
-
SMILES
O=C(NC1=C(C)C=CC=C1C)CN(CC)CC.[H]Cl
-
Synonyms
Lignocaine hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (23)
-
Journal Impact Factor
-
Most Recent
-
Nat Methods
2021 Jul;18(7):788-798. PMID: 34127857 -
Nat Commun
Molecular determinant of low-voltage dependence of human Nav1.7 inactivation revealed by efficacy-based Nav1.7 selective inhibitor. [Abstract]2026 Feb 10;17(1):2559. PMID: 41667447 -
Sci Adv
A worm-like nucleic acid nanostructure for gene delivery and endosomal escape via ClC3 ion exchanger. [Abstract]2026 Mar 6;12(10):eadw0891. PMID: 41790895 -
Sci Adv
EphB1-NR2B receptor signaling in glutamatergic neurons of the ventroposteromedial thalamic nucleus regulates emergence from anesthesia. [Abstract]2025 Dec 5;11(49):eadw7972. PMID: 41348875 -
J Neuroinflammation
Lidocaine alleviates morphine tolerance via AMPK-SOCS3-dependent neuroinflammation suppression in the spinal cord. [Abstract]2017 Nov 2;14(1):211. PMID: 29096659
Lidocaine hydrochloride purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2017 Nov 2;14(1):211. [Abstract]
Immunoblot results demonstrate that Lidocaine inhibits Morphine-induced upregulation of phosphorylation of p38 MAPK, but not the p38 total protein.
-
Stem Cell Res Ther
Local anesthetics impair the growth and self-renewal of glioblastoma stem cells by inhibiting ZDHHC15-mediated GP130 palmitoylation. [Abstract]2021 Feb 4;12(1):107. PMID: 33541421
Lidocaine hydrochloride purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2021 Feb 4;12(1):107. [Abstract]
RT-PCR analysis of ZDHHC15 mRNA levels in GSCs treated with different concentrations (5, 10, and 20 μM) of Prilocaine, Lidocaine, Procaine, and Ropivacaine. β-Actin was used as a loading control.
Lidocaine hydrochloride purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2021 Feb 4;12(1):107. [Abstract]
Local anesthetics Prilocaine, Lidocaine (5-20 μM, 24-48 h), Procain, and Ropivacaine impaired cell survival through inhibition of ZDHHC15 expression.
Lidocaine hydrochloride purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2021 Feb 4;12(1):107. [Abstract]
Representative images showing U251 GSCs maintained under neurosphere conditions for 7 days after transfection with ZDHHC15 shRNA or treatment with prilocaine, lidocaine, procaine, or ropivacaine (20 μM).
Lidocaine hydrochloride purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2021 Feb 4;12(1):107. [Abstract]
Representative images showing U251 GSCs maintained under neurosphere conditions for 7 days after transfection with ZDHHC15 shRNA or treatment with prilocaine, lidocaine, procaine, or ropivacaine (20 μM). GSC neurospheres of all categories were stained for stem and differentiated cell markers as indicated. Cells were stained with antibodies against nestin and SOX2 for neural stem cell markers, and antibody staining of GFAP and MAP 2 were used as markers of differentiated cells. DAPI (4′,6-diamidino-2-phenylindole) was used as a nuclear stain.
Lidocaine hydrochloride purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2021 Feb 4;12(1):107. [Abstract]
The expression of GP130 in U251 GSCs (monolayer culture) transfected with ZDHHC5 shRNA and treated with Prilocaine, Lidocaine, Procaine, and Ropivacaine (20 μM) for 48 h was analyzed by immunofluorescence staining. Scale bar, 100 μm.
Lidocaine hydrochloride purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2021 Feb 4;12(1):107. [Abstract]
GSCs were transfected with ZDHHC5 shRNA or treated with Prilocaine, Lidocaine, Procaine, and Ropivacaine (20 μM) and harvested after 48 h. Cellular fractionation was performed to separate cytosolic and membrane fractions.
-
Transl Psychiatry
Stellate ganglion block diminishes consolidation of conditioned fear memory in mice by inhibiting the locus coeruleus to the basolateral amygdala neural circuit. [Abstract]2025 May 17;15(1):172. PMID: 40382311 -
J Ethnopharmacol
Traditional Chinese Medicine YangxinDingji alleviates arrhythmias through inhibition of sodium and L-type calcium channels. [Abstract]2025 May 12:347:119803. PMID: 40239882 -
Biomater Adv
2026 Jan:178:214452. PMID: 40876091 -
Drug Des Devel Ther
Dexmedetomidine Prolongs Lidocaine Intravenous Regional Anesthesia in Rats by Blocking the Hyperpolarization-Activated Cation Current. [Abstract]2024 Apr 9:18:1103-1114. PMID: 38618283 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Int Immunopharmacol
Lidocaine inhibits influenza a virus replication by up-regulating IFNα4 via TBK1-IRF7 and JNK-AP1 signaling pathways. [Abstract]2023 Feb:115:109706. PMID: 36638664 -
Mol Med Rep
Lidocaine attenuates hypoxia/reoxygenation‑induced inflammation, apoptosis and ferroptosis in lung epithelial cells by regulating the p38 MAPK pathway. [Abstract]2022 May;25(5):150. PMID: 35244190 -
PLoS Pathog
Picornavirus infection enhances aspartate by the SLC38A8 transporter to promote viral replication. [Abstract]2023 Feb 3;19(2):e1011126. PMID: 36735752 -
Phytochemistry
Discovery of GABA-containing cyclic peptides from the cold-seep-derived fungus Aspergillus unguis SCSIO 41322 for the treatment of inflammatory bowel disease. [Abstract]2026 Aug:248:114929. PMID: 41997396 -
Reprod Toxicol
2025 May:134:108895. PMID: 40097051 -
Eur Spine J
Effect of species, concentration and volume of local anesthetics on intervertebral disk degeneration in rats with discoblock. [Abstract]2022 Nov;31(11):2960-2971. PMID: 36152221 -
-
Neurogastroenterol Motil
Lidocaine ameliorates intestinal barrier dysfunction in irritable bowel syndrome by modulating corticotropin-releasing hormone receptor 2. [Abstract]2023 Nov;35(11):e14677. PMID: 37736684 -
PLoS One
The efficacy and safety of lignocaine-embedded dissolvable microneedle versus EMLA for topical analgesia in adults undergoing venepuncture: A single-centre, parallel-group, double-blind randomised clinical trial protocol in a tertiary care setting. [Abstract]2025 Nov 4;20(11):e0335932. PMID: 41187145 -
Dig Dis Sci
Lidocaine Inhibits Hepatocellular Carcinoma Development by Modulating circ_ITCH/miR-421/CPEB3 Axis. [Abstract]2021 Dec;66(12):4384-4397. PMID: 33433806 -
-
Solvent & Solubility
H2O : ≥ 100 mg/mL (369.28 mM)
DMSO : ≥ 100 mg/mL (369.28 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.23 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.23 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 120 mg/mL (443.13 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582(Pt 1):11. [Content Brief]
[2]. Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19(1):233. [Content Brief]
[3]. Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113(1):31-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.6928 mL | 18.4638 mL | 36.9276 mL | 92.3191 mL |
| 5 mM | 0.7386 mL | 3.6928 mL | 7.3855 mL | 18.4638 mL | |
| 10 mM | 0.3693 mL | 1.8464 mL | 3.6928 mL | 9.2319 mL | |
| 15 mM | 0.2462 mL | 1.2309 mL | 2.4618 mL | 6.1546 mL | |
| 20 mM | 0.1846 mL | 0.9232 mL | 1.8464 mL | 4.6160 mL | |
| 25 mM | 0.1477 mL | 0.7386 mL | 1.4771 mL | 3.6928 mL | |
| 30 mM | 0.1231 mL | 0.6155 mL | 1.2309 mL | 3.0773 mL | |
| 40 mM | 0.0923 mL | 0.4616 mL | 0.9232 mL | 2.3080 mL | |
| 50 mM | 0.0739 mL | 0.3693 mL | 0.7386 mL | 1.8464 mL | |
| 60 mM | 0.0615 mL | 0.3077 mL | 0.6155 mL | 1.5387 mL | |
| 80 mM | 0.0462 mL | 0.2308 mL | 0.4616 mL | 1.1540 mL | |
| 100 mM | 0.0369 mL | 0.1846 mL | 0.3693 mL | 0.9232 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.